伊布替尼导入后维奈克拉联合伊布替尼治疗复发/难治性慢性淋巴细胞白血病:SAKK 34/17试验
SAKK 34/17是一项单臂、多中心、2期试验,评估延长伊布替尼导入(6个月)后维奈克拉联合伊布替尼(至少24个月)方案治疗复发/难治性慢性淋巴细胞白血病(CLL)的疗效。30例入组患者中,意向性分析显示40.0%达到不可测微小残留病(uMRD)的完全缓解或伴不完全骨髓恢复的完全缓解(CR/CRi),53.3%在骨髓和外周血中达到uMRD。伊布替尼导入后57.1%患者转为肿瘤溶解综合征(TLS)低风险。
要点
- 延长伊布替尼导入至6个月后,57.1%的复发/难治性CLL患者转为TLS低风险。
- 意向性分析中40.0%患者达到uMRD CR/CRi,53.3%在骨髓和外周血中达到uMRD。
- 第31周期时无进展生存率为89.9%。
核心结论
- 延长维奈克拉联合伊布替尼的治疗时长可能有助于提高疗效,本研究结果支持这一观点。
研究设计与样本
- SAKK 34/17是一项单臂、多中心、2期试验,评估改良维奈克拉联合伊布替尼方案在复发/难治性CLL患者中的疗效。
- 不允许既往暴露于BTK或BCL2抑制剂。
- 伊布替尼导入期延长至6个月以降低肿瘤负荷和相关TLS风险,维奈克拉联合伊布替尼治疗期延长至至少24个月以提高uMRD(10⁻⁴)率。
主要发现
- 30例入组复发/难治性CLL患者中,意向性分析显示40.0%达到uMRD CR/CRi。
- 53.3%的患者在骨髓和外周血中达到uMRD。
- 伊布替尼导入期后,57.1%的患者达到TLS低风险。
- 第31周期时,无进展生存率为89.9%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The combination of ibrutinib plus venetoclax (IV) in chronic lymphocytic leukemia (CLL) treatment leverages their complementary mechanisms of action. Studies investigating IV typically begin with a short initial course of ibrutinib, followed by venetoclax introduction for a limited duration, typically 12 months. The Swiss Group for Clinical Cancer Research (SAKK) 34/17 study is a single-arm, multicenter, phase 2 trial evaluating the effectiveness of a modified IV schedule in patients with relapsed/refractory (R/R) CLL. No prior exposure to BTK or BCL2 inhibitors was allowed. The lead-in phase with ibrutinib was extended to 6 months to reduce the tumor burden and related tumor lysis syndrome (TLS) risk. Additionally, the treatment phase with IV is prolonged to a minimum of 24 months to enhance the undetectable minimal residual disease (uMRD; 10-4) rate. The primary end point was the rate of complete response or complete response with incomplete bone marrow recovery (CR/CRi) with uMRD in both bone marrow (BM) and peripheral blood (PB). Secondary end points included assessing the proportion of patients transitioning to a low-risk category for TLS after receiving ibrutinib lead-in. Of the 30 enrolled patients with R/R CLL, 40.0% achieved uMRD CR/CRi by intention-to-treat analysis, and 53.3% showed uMRD in the BM and PB. After the lead-in period with ibrutinib, 57.1% of patients achieved a low risk of TLS. At cycle 31, the progression-free survival rate was 89.9%. These results contribute to the increasing body of evidence supporting the idea that a longer IV duration is beneficial for enhancing therapeutic effectiveness. This trial was registered at www.clinicaltrials.gov as #NCT03708003.
引用
- Condoluci A, Romano I, Dietrich D, et al. Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial. Blood. 2025. PMID: 40009495. doi:10.1182/blood.2024026879
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。